Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
9
×
new york blog main
new york top stories
9
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
clinical trials
national top stories
startups
deals
fda
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
seattle blog main
seattle top stories
springworks therapeutics
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech ipos
glaxosmithkline
medical device
nonalcoholic steatohepatitis
pfizer
president trump
What
biotech
9
×
days
roundup
companies
drug
ipo
new
research
week
annual
attention
bio
control
drugs
hasn’t
ipos
life
medicines
news
satsuma
science
slowed
springworks
startup
street
today
wall
welcomed
according
activity
ahead
aiming
aims
akcea
alzheimer’s
ambien
ambys
american
approach
arrival
Language
unset
Current search:
xconomy.com
×
" new york top stories "
×
biotech
×
" national blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More